The combination of Nivolumab and HuMax-IL8 (CXCL8 inhibitor) was tested in multiple cancers, including renal cell carcinoma (RCC), malignant melanoma, NSCLC, hepatocellular carcinoma (HCC), prostate carcinoma (PC), and squamous cell carcinoma of head and neck (SCCHN) (NCT04572451, NCT04123379, NCT03689699, NCT04848116). The gene discussed is CXCL8; the disease is pachyonychia congenita.